Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
about
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@en
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@nl
type
label
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@en
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@nl
prefLabel
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@en
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@nl
P2093
P2860
P356
P1476
Efficacy of the dual PI3K and ...... elogenous leukemia cell lines.
@en
P2093
Chuntuan Li
Huifang Xiao
Pengliang Xin
Qunyi Peng
Xiongpeng Zhu
Yuanling Huang
P2860
P304
P356
10.2147/DDDT.S132092
P407
P577
2017-04-03T00:00:00Z